Part, Chapter, Paragraph
1 I, 2. 10. 3 | support a common approach to patient identifiers and electronic
2 I, 2. 10. 4 | to match product data to patient data, verification of patient
3 I, 2. 10. 4 | patient data, verification of patient identity via a wristband,
4 I, 2. 10. 4 | implant serial numbers in patient records and central registries,
5 I, 2. 10. 4 | admissions are likely to incur patient safety incidents, which
6 I, 2. 10. 4 | pharmacists before they reach the patient, only 2% of administration
7 I, 2. 10. 4 | point of delivery to the patient, is an extremely effective
8 I, 2. 10. 4(12)| Simple technology for safer patient car – UK Departament of
9 I, 2. 10. 4(19)| Simple technology for safer patient care – UK Depertament of
10 I, 2. 10. 4 | from product manufacture to patient treatment, is imperative
11 I, 2. 10. 4 | healthcare settings, such as patient identification codes on
12 I, 2. 10. 4(22)| Simple technology for safer patient care” UK Department of Health –
13 II, 5. 1. 2 | 5.1.2. Patient centeredness~ ~More than
14 II, 5. 1. 2 | directly dependent on how the patient and his/her family have
15 II, 5. 1. 2 | bearer of a disease, the patient, is a unique person totally
16 II, 5. 1. 2 | totally different from another patient who may suffer from the
17 II, 5. 1. 2 | dimensions for helping a patient, patient-centeredness can
18 II, 5. 1. 2 | simultaneously into account. Patient care oscillates between
19 II, 5. 1. 2 | dimensions that deal with patient rehabilitation, home visiting
20 II, 5. 1. 2 | visiting nurses, therapeutic patient education and patient associations
21 II, 5. 1. 2 | therapeutic patient education and patient associations who all participate
22 II, 5. 1. 2 | even no dialogue with his patient.~ ~Chronic diseases and
23 II, 5. 1. 2 | spiritual dimensions of the patient. Of course, coping and psychological
24 II, 5. 1. 2 | may vary depending on each patient, but are also the result
25 II, 5. 1. 3 | 5.1.3. Therapeutic patient education~ ~The WHO produced
26 II, 5. 1. 3 | document in 1998 on therapeutic patient education (Report of a WHO
27 II, 5. 1. 3 | Working Group on Therapeutic Patient Education. Continuing education
28 II, 5. 1. 3 | partnership between the patient and his health care professional
29 II, 5. 1. 3 | skills which could help the patient to have a major role in
30 II, 5. 1. 3 | adherence.~ ~Therapeutic patient education should enable
31 II, 5. 1. 3 | and illness. Therapeutic patient education has been designed
32 II, 5. 1. 3 | that practice therapeutic patient education, hoping therefore
33 II, 5. 1. 3 | global need. Therapeutic patient education is a systemic,
34 II, 5. 1. 3 | takes into account:~· the patient’s adaptation processes (
35 II, 5. 1. 3 | treatment and care.~Therapeutic patient education is about the patient’
36 II, 5. 1. 3 | patient education is about the patient’s daily life and psychosocial
37 II, 5. 1. 3 | environment, and also involves the patient’s family and his/her closest
38 II, 5. 1. 3 | course of the disease, to the patient and to his/her daily life.
39 II, 5. 1. 3 | the long-term care of the patient and has to be structured,
40 II, 5. 1. 3 | systematically provided to each patient using different means. We
41 II, 5. 1. 3 | their condition. Therapeutic patient education is designed, therefore,
42 II, 5. 1. 3 | our society. Therapeutic patient education is essential for
43 II, 5. 1. 3 | its benefits. Therapeutic patient education is education managed
44 II, 5. 1. 3 | and designed to enable a patient (or a group of patients
45 II, 5. 1. 4 | In healthcare, as the patient needs information about
46 II, 5. 1. 4 | manage the disease. The patient also needs information about
47 II, 5. 1. 4 | concerns his/hercare. As a patient, the affected person should
48 II, 5. 2. 3 | their initial admission. The patient is usually stabilized and
49 II, 5. 2. 3 | possible to identify the patient when he/she is re-admitted
50 II, 5. 2. 3 | possible to know if the patient may have experienced an
51 II, 5. 2. 3 | which allows to identify the patient when he/she is re-admitted
52 II, 5. 2. 5 | interventions fail to bring the patient’s blood lipids or blood
53 II, 5. 2. 6 | the overall CV risk of the patient considered is high, a pharmacological
54 II, 5. 2. 6 | which may be present in the patient. The association of two
55 II, 5. 3. 2 | population level cancer patient data are becoming more and
56 II, 5. 3. 2 | were intended to improve patient confidentiality, but in
57 II, 5. 3. 2 | programme planning, and patient care improvement;~· cancer
58 II, 5. 3. 2 | global comparison regarding patient access to cancer drugs by
59 II, 5. 3. 7 | global comparison regarding patient access to cancer drugs” (
60 II, 5. 3. 7 | facilitate, and not delay, patient access.~· Ensure that appropriate
61 II, 5. 3. 7 | scientific research and patient community (Haward and Borras,
62 II, 5. 3. 7 | best decisions for each patient’s diagnosis, treatment and
63 II, 5. 3. 8 | consideration the cancer patient needs: achieve full knowledge
64 II, 5. 3. 8 | function of cancer type, patient age and rehabilitation requirements
65 II, 5. 4. 1 | average annual costs per patient with type 2 diabetes were
66 II, 5. 4. 2 | identifier assigned to the patient. This way, denominators
67 II, 5. 4. 6 | particularly well to diabetes is patient empowerment. This process
68 II, 5. 4. 6 | stakeholders, including patient and civil society organisations,
69 II, 5. 4. 7 | setting, where the diabetic patient is met and where there is
70 II, 5. 4. 8 | population-based equitable patient care: the Tayside Regional
71 II, 5. 4. 8 | A networked electronic patient record system for diabetes,
72 II, 5. 5. 1 | medicin3es on DDD levels per patient.~ ~
73 II, 5. 5. 3 | place of residence of the patient. Two age categories are
74 II, 5. 5. 3 | these recommendations and patient’s compliance.~For a multitude
75 II, 5. 5. 3 | settings and routine care (patient population, artificial circumstances,
76 II, 5. 5. 3 | tendencies of efficacy in certain patient groups but give little to
77 II, 5. 5. 3 | strategy for the individual patient.~Lack and misallocation
78 II, 5. 5. 3 | results from the Schizophrenia Patient Outcomes Research Team (
79 II, 5. 5. 3 | schizophrenia: Lessons from the Patient Outcomes Research Team (
80 II, 5. 5. 3 | the attentiveness of the patient and his/her family, on the
81 II, 5. 5. 3 | in a previously healthy patient with epilepsy in whom no
82 II, 5. 5. 3 | Nashef et al, 1995). The patient at risk for SUDEP is a young
83 II, 5. 5. 3 | varies depending on the patient’s or the health authority’
84 II, 5. 5. 3 | and Sander, 2005). From a patient’s perspective, the risk
85 II, 5. 5. 3 | imaging data of each enrolled patient. Such networks can be easily
86 II, 5. 5. 3 | 2000): Epilepsy from the patient’s perspective: review of
87 II, 5. 5. 3 | including the National Patient Registry (Koch-Henriksen
88 II, 5. 5. 3 | as total annual cost per patient in 2005, total direct costs (
89 II, 5. 5. 3 | in the study estimates.~A patient with mild disability at
90 II, 5. 5. 3 | unpredictable also in the same patient. The following categorisation
91 II, 5. 5. 3 | by both the medical and patient community;~· It commits
92 II, 5. 5. 3 | professionalisation of the patient’s status (i.e. the strengthening
93 II, 5. 5. 3 | considerably affects the patient’s quality of life and leads
94 II, 5. 5. 3 | with an average cost per patient of €7,600.~ ~Figure 5.5.
95 II, 5. 5. 3 | average cost are €3,400 per patient, whereas the cost for severely
96 II, 5. 5. 3 | patients reach €9,200 per patient (HY IV).~ ~ ~Figure 5.5.
97 II, 5. 5. 3 | the future.~The cost per patient was found to be about five
98 II, 5. 5. 3 | health-related quality of life and patient utilities of Parkinson’s
99 II, 5. 6. 3 | risk for the individual patient over a time period that
100 II, 5. 6. 6 | Rheumatoid Arthritis: the Patient Perspective. Ann Rheum Dis
101 II, 5. 6. 6 | Anderson S, Anderson RJ (2000): Patient desire and reasons for specialist
102 II, 5. 6. 6 | and Akesson K (2006): The Patient with Osteoporosis. In: Osteoporosis
103 II, 5. 7. 2 | and reliable individual patient data on the incidence and
104 II, 5. 7. 2 | able to provide individual patient data covering their whole
105 II, 5. 7. 2 | will only include complete patient data in another few years.
106 II, 5. 7. 2 | availability of individual patient data within one European
107 II, 5. 7. 2 | Mediterranean Sea. The individual patient data are used for epidemiological
108 II, 5. 7. 2 | incidence, prevalence and patient survival. These are published
109 II, 5. 7. 2 | registries including individual patient data collect at least the
110 II, 5. 7. 2 | birth and gender of each patient starting RRT in their coverage
111 II, 5. 7. 2 | provide complete individual patient data for the whole country
112 II, 5. 7. 3 | considerable differences in patient survival (van Dijk et al,
113 II, 5. 7. 5 | measures will be based on patient outcomes, referral patterns
114 II, 5. 7. 5 | when deemed necessary. The patient association - which is supported
115 II, 5. 7. 6 | far below the demand. As patient survival and quality of
116 II, 5. 8. 3 | patients and in the same patient over time. Co-morbidities
117 II, 5. 8. 3 | understanding of their impact on the patient and disease management:~•
118 II, 5. 8. 3 | direct annual costs per patient were about 1 200, 1 600
119 II, 5. 8. 3 | medical cost of every COPD patient was estimated at 4,366 euro
120 II, 5. 8. 3 | average direct costs per patient were estimated to be 909€
121 II, 5. 8. 3 | An analysis of the Danish Patient Registry for patients admitted
122 II, 5. 8. 3 | the cost of treatment per patient was 1.017 Euro. It was found
123 II, 5. 9. FB | exaggerated reaction by the patient’s immune system to an allergen
124 II, 5. 9. 3 | the cost of treatment per patient was 750.18 Euro (Vrbica,
125 II, 5. 9. 4 | with ARIA guidelines, every patient with allergic rhinitis should
126 II, 5. 9. 5 | on preventive measures, patient education and self-management
127 II, 5. 9. 6 | subjective perceptions of the patient. The assessment of HRQoL
128 II, 5. 9. 6 | symptoms available for every patient in the world.~ ~
129 II, 5. 9. 7 | structured review of recent patient surveys, BMC Pulmonary Medicine
130 II, 5. 11. 3 | for the most part of the patient’s suffering and incapacitation:
131 II, 5. 11. 3 | manifestations long after a patient stops wearing the nickel-releasing
132 II, 5. 11. 3 | is highly variable from patient to patient, and up to 10-
133 II, 5. 11. 3 | variable from patient to patient, and up to 10-20% of patients
134 II, 5. 14. 3 | the face of disease and patient management. In France, 40%
135 II, 5. 14. 7 | multidimensional aspects of patient perceived needs, desires
136 II, 5. 14. 7 | approach to help determine patient’s needs in order to assure
137 II, 5. 15. 5 | rare diseases diagnosis and patient care in the EU are expected
138 II, 5. 15. 5 | recognition and for improved care. Patient organizations now play an
139 II, 9. 1. 2 | information systems using unique patient identifiers. EUROCAT is
140 II, 9. 1. 2 | European directive regarding patient consent. Although a reasonable
141 II, 9. 3. 1 | important determinant in patient selection for treatment
142 II, 9. 3. 1 | Adams A, et al, (2006): Patient characteristics and inequalities
143 II, 9. 4. 5 | financial resources of a patient and his or her family. A
144 III, 10. 2. 1 | care and ensure effective patient referral~ ~Focusing on health
145 III, 10. 2. 3 | overall CVD risk of the patient is high, a pharmacological
146 IV, 11. 1. 3 | standards. The focus on patient rights and patient safety
147 IV, 11. 1. 3 | focus on patient rights and patient safety has been integral
148 IV, 11. 1. 3 | role of the individual or patient is another factor requiring
149 IV, 11. 1. 3 | technical efficiency and the patient’s experience.~ ~
150 IV, 11. 1. 5 | availability, respect, timeliness, patient/care experience, choice/
151 IV, 11. 1. 5 | integral in quality of care is patient safety, which is discussed
152 IV, 11. 1. 5 | yet lacks of impact on patient empowerment (Mainz and Bartels,
153 IV, 11. 1. 5 | diabetes, mental health, patient safety and primary care/
154 IV, 11. 1. 5 | corresponds to the needs of the patient. Strategies to ensure appropriateness
155 IV, 11. 1. 5 | and information systems, patient surveys, clinical governance
156 IV, 11. 1. 5 | products to meet the individual patient’s need, thus require an
157 IV, 11. 1. 5 | related to information), patient experiences and additional
158 IV, 11. 1. 5 | the GP contract includes patient documentation requirements.
159 IV, 11. 1. 5 | process seek to monitor patient outcomes through specific
160 IV, 11. 1. 5 | target include the setting of patient blood pressure and cholesterol
161 IV, 11. 1. 5 | aspects of care provision.~ ~Patient and public experiences~ ~
162 IV, 11. 1. 5 | experiences~ ~Public and patient surveys shed light on the
163 IV, 11. 1. 5 | quality of public services~ ~Patient safety~ ~Patient safety
164 IV, 11. 1. 5 | services~ ~Patient safety~ ~Patient safety is increasingly recognized
165 IV, 11. 1. 5 | In the UK, the National Patient Safety Agency was established
166 IV, 11. 1. 5 | established in 2001 to improve patient safety by reducing the risk
167 IV, 11. 1. 5 | help raise awareness on patient safety issues. Denmark is
168 IV, 11. 1. 5 | formal system for ensuring patient safety.~ ~Patient safety
169 IV, 11. 1. 5 | ensuring patient safety.~ ~Patient safety can be improved through
170 IV, 11. 1. 5 | professional training courses in patient safety should demonstrate
171 IV, 11. 1. 5 | all personnel to protect patient safety, regardless of the
172 IV, 11. 1. 5 | the World Alliance for Patient Safety was formed in 2002
173 IV, 11. 1. 5 | of promoting a culture of patient safety (McCarthy and Blumenthal,
174 IV, 11. 1. 5 | follow eight steps to reduce patient safety concerns. This resulted
175 IV, 11. 1. 5 | one-day decrease in average patient length-of-stay and 43 less
176 IV, 11. 1. 5 | early signs of declining patient health to avoid acute crises.
177 IV, 11. 1. 5 | represent a concern for both patient safety and the finances
178 IV, 11. 1. 5 | avoiding medical errors, the patient is also seen as having a
179 IV, 11. 1. 5 | with the health system~ ~Patient and public satisfaction
180 IV, 11. 1. 5 | measured through population or patient surveys and opinion polls.
181 IV, 11. 1. 5 | based on public rather than patient experiences. The European
182 IV, 11. 1. 6 | survival rates, waiting times, patient experiences and longer-term
183 IV, 11. 1. 6 | Fee-for-service if higher income, patient capitation if lower patient
184 IV, 11. 1. 6 | patient capitation if lower patient income.~ ~Salary. Fee-for-service
185 IV, 11. 1. 6 | Fee-for-service if higher patient income,~capitation if lower
186 IV, 11. 1. 6 | income,~capitation if lower patient income.~ ~ ~Blended payment (
187 IV, 11. 1. 6 | clinical outcomes and enhance patient safety and satisfaction
188 IV, 11. 1. 6 | inclusive flat sum for a patient’s treatment according to
189 IV, 11. 1. 6 | costs of treating a given patient and to reimburse providers
190 IV, 11. 1. 6 | with different systems of patient classification, there is
191 IV, 11. 2. 1 | prevention and management of patient risk factors in addition
192 IV, 11. 3. 2 | the payer beyond which the patient must bare the additional
193 IV, 11. 4 | health policies that are patient focused and seek to achieve
194 IV, 11. 4 | incorporation of population and patient preferences in health economic
195 IV, 11. 6. 4 | not fully reimbursed the patient must pay the remainder out
196 IV, 11. 6. 4 | on measures of changes in patient outcomes, that is, patient
197 IV, 11. 6. 4 | patient outcomes, that is, patient health status and satisfaction,
198 IV, 11. 6. 5 | Provider payments and patient charges as policy tools
199 IV, 11. 6. 5 | al. (2006): Pathways to patient safety: the use of rules
200 IV, 11. 6. 5 | guidelines in health care. Patient Safety: Research into Practice.
201 IV, 11. 6. 5 | HOPE.~ ~Howe A (2006): Patient safety: education, training
202 IV, 11. 6. 5 | professional development. Patient Safety: Research into Practice.
203 IV, 11. 6. 5 | The appropriate role for patient cost sharing. Critical challenges
204 IV, 11. 6. 5 | Santé.~ ~Tomes N (2007): “Patient empowerment and the dilemmas
205 IV, 12. 2 | interventions fail to bring the patient’s blood lipids or blood
206 IV, 12. 2 | cancer research, quality of patient care, the attractiveness
207 IV, 12. 2 | were intended to improve patient confidentiality, but in
208 IV, 12. 2 | involving stakeholders including patient and civil society organisations
209 IV, 12. 3 | cooperation of health systems and patient rights in cross-border health
210 IV, 12. 3 | care. A draft directive on patient’s rights in cross-border
211 IV, 12. 4 | nosocomial diseases); and~· patient safety.~ ~ ~Independent
212 IV, 12. 5 | Promote measures to improve patient safety through high-quality
213 IV, 12. 5 | of cross-border care and patient and health professional
214 IV, 12. 10 | measures with regard to patient safety (examples):~Federal
215 IV, 12. 10 | driving).~German Coalition for Patient Safety (Aktionsbündnis Patientensicherheit)–
216 IV, 12. 10 | manufactures, insurance funds, and patient organizations to improve
217 IV, 12. 10 | organizations to improve patient safety, see www. e~„Forum
218 IV, 12. 10 | safety, see www. e~„Forum Patient safety“ – provided by German
219 IV, 12. 10 | published.~Commission on Patient Safety and Quality~established
220 IV, 12. 10 | The Commisison~includes patient representatives and~has
221 IV, 12. 10 | investigations on issues relating to patient safety. HIQA incorporates
222 IV, 13. 5 | level reflection process on patient mobility and healthcare
223 IV, 13. 5 | nosocomial diseases); and~· patient safety.~ ~An improved co-operation
224 IV, 13. 7. 5 | cross-border health services, and patient safety. In order to satisfy
225 IV, 13. 7. 5 | only refers to individual patient care. Thus, only paragraph
226 Key, Ap5. 0. 0 | particles~particulate~pathogens~patient~patient-centeredness~patients~
